Jeremy Barton, Pfizer to Speak at 4th Cancer Targets & Therapeutics - Feb 25-26, 2013 in Las Vegas
Jeremy Barton, VP, Head of Oncology Clinical Research at Pfizer to Give a Keynote Presentation at the 4th Cancer Targets & Therapeutics Conference (Feb 25-26, 2013 in Las Vegas, NV).
- (1888PressRelease) December 06, 2012 - Jeremy Barton, Vice President, Head of Oncology Clinical Research at Pfizer will give a keynote presentation on "The Potential of Antibody Drug Conjugates: Hype or Reason to Hope?" at the 4th Cancer Targets & Therapeutics Conference (Feb 25-26, 2013 in Las Vegas)
The importance of selecting a target which is preferentially expressed on tumor cells has long been self evident but what has become apparent in the last 5 years is the increasing complexity of the underlying technology used to make these conjugates. The type of therapeutic agent, the way in which it is linked to the antibody and the site of linkage to the antibody can all have dramatic impacts on the pharmacokinetics, safety and efficacy of the total construct. Dr. Barton's presentation will review some of the exciting data that have already been generated and will objectively review some of the challenges which must be overcome in the future in order to maximize the promise of ADCs as a new class of therapeutic agent.
Topics to be discussed:
• Review of past history of ADC development
• Understanding of technological challenges in constructing an ADC
• Review of available technologies
• Importance of patient selection strategies
Dr. Barton's special interest is the interface between Research and Early Development to Proof of Concept with emphasis on integration of a companion diagnostic strategy into drug development plans.
This conference is part of our larger 2nd Novel Cancer Therapeutics Summit, which consists of two other parallel conferences, the 2nd Oncology Partnering & Deal-Making conference and the 3rd Ubiquitin Research & Drug Discovery conference.
For more information, please visit www.gtcbio.com.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam